


COPD/Emphysema Patient Information Form

Are your current medications adequately controlling your COPD/emphysema symptoms?

Find out if the Zephyr® Valve is right for you.

Zephyr Valve treatment — a minimally invasive procedure to help improve your breathing and quality of life. The procedure typically takes less than an hour and has been proven to greatly reduce the hyperinflation that makes it harder for patients with emphysema to breathe. The valves are placed by bronchoscopy which requires no incisions or cutting, so the benefits are achieved without many of the risks of traditional surgical options.¹



Name:

- | | | |
|---|------------|-----------|
| Have you ever been told by a doctor that you have COPD or emphysema? | Yes | No |
| Do you take inhaled breathing medications on a daily basis? | Yes | No |
| Do you frequently stop to catch your breath or go slowly while climbing stairs or doing other activities? | Yes | No |
| Has your breathing prevented you from doing activities you once enjoyed? | Yes | No |
| Do you still have COPD/Emphysema symptoms despite using COPD medications? | Yes | No |
| Are you interested in learning more about Zephyr Valve Treatment? | Yes | No |

These questions will be reviewed by your healthcare provider during your appointment and you will have the opportunity to discuss the Zephyr Valve treatment option.

Important Safety Information: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. Complications can include but are not limited to pneumothorax (tear in the lung), worsening of COPD symptoms, hemoptysis, pneumonia, and, in rare cases, death. The Zephyr Valve is contraindicated in patients who have not quit smoking. Please talk with your physician about other contraindications, warnings, precautions, and adverse events. Only a trained physician can decide whether a particular patient is an appropriate candidate for treatment with the Zephyr Valve.

¹ Criner, G et al. Am J Resp Crit Care Med. 2018 Nov 1;198(9):1151–1164.

This material is not intended for use in France, Denmark, Switzerland, Belgium, Cyprus, France, Greece, Ireland, Italy, Luxembourg, Netherlands, Poland, Portugal, Slovakia, and Spain.

For Office Use Only:

Inclusion Criteria

The information above should be used during your patient's evaluation for treatment. Patients should be considered for referral if they are breathless despite optimal medical management (mMRC ≥2) and have an FEV₁ of ≤50% predicted.

Notes:

Pulmonx Corporation

700 Chesapeake Drive
Redwood City, CA 94063

© 2022–Present Pulmonx Corporation or its affiliates. All rights reserved. All trademarks herein are the property of Pulmonx Corporation and its affiliates.

GL0-EN-1279-v1 Patient Consultation Request Form PCP

